Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Reports
Email Alerts
Contact Us
Investors & News
Latest News
Nov 24,2020
Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering
Nov 20,2020
Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering
Nov 05,2020
Stealth BioTherapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
November 23, 2020
Form 6-K : Report of Foreign Issuer
HTML
November 20, 2020
Form 424B5 : Prospectus filed pursuant to Rule 424(b)(5)
HTML
Reports
Latest Presentations
October 27, 2020
Investor Presentation October 2020
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
Presentations
Events
November 05, 2020
Stealth BioTherapeutics to Report Third Quarter 2020 Financial Results at 8:30am EST
Webcast
September 23, 2020
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 1:40 pm ET
Webcast
Financial Calendar
Media Relations
Amelia Stetler, 617-762-2562
media@stealthbt.com
Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com
